Table 6.
Trials using anti-EGFR mAbs plus bevacizumab in chemotherapy naïve mCRC selected by KRAS.
| Trial (author) | Phase | KRAS | Protocol | Number enrolled | Results | HR (95% CI) | P value | |
|---|---|---|---|---|---|---|---|---|
| PFS | OS | |||||||
| — (Tol et al.) [27] | III | WT | Capecitabine + oxaliplatin + bevacizumab + cetuximab | 158 | 10.5 mos. | 21.8 mos. | PFS: NR | 0.3 |
| Capecitabine + oxaliplatin + bevacizumab | 156 | 10.6 mos. | 22.4 mos. | OS: NR | 0.64 | |||
| MUT | Capecitabine + oxaliplatin + bevacizumab + cetuximab | 98 | 8.1 mos. | 17.2 mos. | PFS: NR | 0.003 | ||
| Capecitabine + oxaliplatin + bevacizumab | 108 | 12.5 mos. | 24.9 mos. | OS: NR | 0.03 | |||
|
| ||||||||
| PACCE (Hecht et al.) [28] | III | WT | FOLFOX + panitumumab + bevacizumab | 201 | 9.8 mos. | 20.7 mos. | PFS: 1.36 (1.04–1.77) | NR |
| FOLFOX + bevacizumab | 203 | 11.5 mos. | 24.5 mos. | OS: 1.89 (1.30–2.75) | 0.045 | |||
| MUT | FOLFOX + panitumumab + bevacizumab | 135 | 10.4 mos. | 19.3 mos. | PFS: 1.25 (0.91–1.71) | NR | ||
| FOLFOX + bevacizumab | 125 | 11.0 mos. | 19.3 mos. | OS: 1.02 (0.67–1.54) | NR | |||
|
| ||||||||
| — (Saltz et al.) [29] | III | WT | mFOLFOX + bevacizumab | 49 | 10.9 mos. | 18.8 mos. | PFS: NR | 0.99 |
| FOLF + cetuximab + bevacizumab | 46 | 8.8 mos. | 21.5 mos. | OS: NR | 0.96 | |||
| MUT | mFOLFOX + bevacizumab | 36 | 12.1 mos. | 22.4 mos. | PFS: NR | <0.01 | ||
| FOLF + cetuximab + bevacizumab | 33 | 8.0 mos. | 20.3 mos. | OS: NR | 0.11 | |||
WT: wild type, MUT: mutated, PFS: progression free survival, OS: overall survival, and NR: not reported.